Adderall Antitrust Suit Should Stay Buried, 2nd Circ. Hears

Law360, New York (October 4, 2013, 5:46 PM EDT) -- Shire LLC pushed back Friday against two drug wholesalers' bid to revive a consolidated class action alleging Shire stifled generic-drug competition for its blockbuster attention deficit hyperactivity disorder treatment Adderall XR, saying the lower court correctly ruled that Shire's patent licensing agreements didn't raise an antitrust issue.

Shire's brief to the Second Circuit backed a March ruling by U.S. District Judge Victor Marrero dismissing the suit by Louisiana Wholesale Drug Co. Inc. and Value Drug Co. Inc. that claimed Shire artificially inflated prices by holding back...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.